Stoke Therapeutics, Inc. – NASDAQ:STOK

Add to watchlist

$18.3

+7.24

+65.46%

Market open

Closed in 44 minutes

-22.39%

month

-22.39%

quarter

+106.73%

year

Market Cap	609.65M
Enterprise value	N/A

P/E	-3.21
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	25.36
Price/Book	1.70
PEG ratio	0.28
EPS	-2.41

Revenue	7.84M
EBITDA	-116.12M
Income	-108.52M
Revenue Q/Q	-18.16%
Revenue Y/Y	-46.10%

Profit margin	-814.73%
Oper. margin	-841.24%
Gross margin	26.05%
EBIT margin	-841.24%
EBITDA margin	-1480.25%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Stoke Therapeutics Stock Forecast

M Q Y

Last Year

$26.5

Potential upside: 44.80%

Analysts Price target
Financials & Ratios estimates

Stoke Therapeutics, Inc. (NASDAQ:STOK): Profit margin
Jun 2023	-2.48M	-30.65M	1235.55%
Sep 2023	3.30M	-24.54M	-741.9%
Dec 2023	2.80M	-26.95M	-962.1%
Mar 2024	4.21M	-26.37M	-625.57%

Stoke Therapeutics, Inc. (NASDAQ:STOK): Debt to assets
Jun 2023	256919000	66.72M	25.97%
Sep 2023	239889000	66.89M	27.88%
Dec 2023	228342000	68.77M	30.12%
Mar 2024	205182000	64.84M	31.6%

Stoke Therapeutics, Inc. (NASDAQ:STOK): Cash Flow
Jun 2023	-21.8M	23.47M	48K
Sep 2023	-17.26M	14.61M	562K
Dec 2023	-20.64M	14.77M	7.34M
Mar 2024	-24.56M	9.98M	1.71M

Stoke Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Stoke Therapeutics, Inc. (NASDAQ:STOK): Employee count
Aug 2023	117
Sep 2023	117
Oct 2023	117
Nov 2023	117
Dec 2023	117
Jan 2024	117
Feb 2024	117
Mar 2024	110
Apr 2024	110
May 2024	110
Jun 2024	110
Jul 2024	110

Stoke Therapeutics
Hedge Funds Holdings Q1 2023

37.26% -62.74%

of STOK is owned by hedge funds

57 -49

hedge funds hold STOK stock

14.49M -25.79M

shares is hold by hedge funds

STOK hedge funds holdings changes

Stoke Therapeutics
Insider Trading

Stoke Therapeutics, Inc. (NASDAQ:STOK): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	10000
Feb 2024	0	10000
Mar 2024	0	40973
Apr 2024	0	3670755
May 2024	0	110949
Jun 2024	0	10000
Jul 2024	0	12500
Aug 2024	0	10000
Sep 2024	0	1947500
Oct 2024	0	10000
Nov 2024	0	10000
Dec 2024	0	2062849

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	23 Dec 2024	SKORPIOS TRUST 10 percent owner 10 percent owner	Common Stock	2,000,000	$11.5	$23,000,000
Sale	9 Dec 2024	TICHO BARRY officer: CHIEF MEDICAL OFFICER officer: CHIEF MEDICAL OFFICER	Common Stock	2,586	$12.99	$33,595
Sale	9 Dec 2024	ALLAN JONATHAN officer: GENERAL COUNSEL & CORP SEC officer: GENERAL COUNSEL & CORP..	Common Stock	12,114	$13.69	$165,816
Sale	9 Dec 2024	ALLAN JONATHAN officer: GENERAL COUNSEL & CORP SEC officer: GENERAL COUNSEL & CORP..	Common Stock	1,552	$12.99	$20,164
Sale	9 Dec 2024	KAYE EDWARD M. MD director, officer..	Common Stock	6,786	$12.99	$88,157
Sale	9 Dec 2024	KAYE EDWARD M. MD director, officer..	Common Stock	6,786	$12.99	$88,157
Sale	6 Dec 2024	TICHO BARRY officer: CHIEF MEDICAL OFFICER officer: CHIEF MEDICAL OFFICER	Common Stock	13,945	$12.78	$178,189
Sale	6 Dec 2024	ALLAN JONATHAN officer: GENERAL COUNSEL & CORP SEC officer: GENERAL COUNSEL & CORP..	Common Stock	9,696	$12.78	$123,895
Sale	6 Dec 2024	KAYE EDWARD M. MD director, officer..	Common Stock	6,170	$12.78	$78,840
Sale	6 Dec 2024	KAYE EDWARD M. MD director, officer..	Common Stock	6,170	$12.78	$78,840

STOK insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS Filling date: 3 Nov 2021 Issue date: 26 May 2022	3 Nov 2021	26 May 2022
Application	Application ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES Filling date: 26 Aug 2021 Issue date: 26 May 2022	26 Aug 2021	26 May 2022
Application	Application METHODS AND COMPOSITIONS FOR MODULATING SPLICING AND TRANSLATION Filling date: 3 Nov 2021 Issue date: 28 Apr 2022	3 Nov 2021	28 Apr 2022
Application	Application ANTISENSE OLIGOMERS AND USES THEREOF Filling date: 19 Jul 2021 Issue date: 21 Apr 2022	19 Jul 2021	21 Apr 2022
Application	Application ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME Filling date: 23 Jun 2021 Issue date: 24 Mar 2022	23 Jun 2021	24 Mar 2022
Application	Application METHODS AND COMPOSITIONS FOR TREATMENT OF CHOLESTERYL ESTER STORAGE DISEASE Filling date: 3 May 2019 Issue date: 2 Dec 2021	3 May 2019	2 Dec 2021
Application	Application ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES Filling date: 18 Dec 2020 Issue date: 7 Oct 2021	18 Dec 2020	7 Oct 2021
Application	Application ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES Filling date: 23 Oct 2018 Issue date: 2 Sep 2021	23 Oct 2018	2 Sep 2021
Grant	Grant Utility: Antisense oligomers and uses thereof Filling date: 13 Jun 2018 Issue date: 24 Aug 2021	13 Jun 2018	24 Aug 2021
Grant	Grant Utility: Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome Filling date: 14 Dec 2016 Issue date: 10 Aug 2021	14 Dec 2016	10 Aug 2021

Stoke Therapeutics
Executives

Insider	Age	Compensation
Dr. Edward M. Kaye (1949) Chief Executive Officer & Director	76	$958,050
Dr. Barry S. Ticho FACC, M.D., Ph.D. (1960) Chief Medical Officer	65	$662,500
Mr. Stephen J. Tulipano CPA, CPA, MBA (1959) Chief Financial Officer	66	$611,450
Dr. Adrian R. Krainer Ph.D. (1959) Co-Founder, Independent Director & Member of Scientific Advisory Board	66	$39,000

Stoke Therapeutics
Latest News

Tuesday, 24 December 2024
12:51	4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow	zacks.com
Friday, 6 December 2024
12:00	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome	businesswire.com
Thursday, 5 December 2024
11:15	STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug	zacks.com
Monday, 2 December 2024
08:00	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting	businesswire.com
Wednesday, 20 November 2024
10:55	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now	zacks.com
Friday, 8 November 2024
10:55	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade	zacks.com
Tuesday, 5 November 2024
09:16	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Tuesday, 29 October 2024
11:06	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release	zacks.com
Saturday, 7 September 2024
04:03	Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome	seekingalpha.com
Tuesday, 3 September 2024
08:00	Stoke Therapeutics to Present at Upcoming Investor Conferences in September	businesswire.com
Wednesday, 7 August 2024
09:26	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
Tuesday, 16 July 2024
16:30	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	businesswire.com
Tuesday, 18 June 2024
16:30	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	businesswire.com
Friday, 14 June 2024
12:10	Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome	seekingalpha.com
Monday, 3 June 2024
16:30	Stoke Therapeutics to Present at Upcoming Investor Conferences in June	businesswire.com
Friday, 17 May 2024
16:30	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	businesswire.com
Monday, 6 May 2024
09:06	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Thursday, 4 April 2024
16:30	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Business Wire
Wednesday, 27 March 2024
09:51	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data	Zacks Investment Research
Monday, 25 March 2024
18:10	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 29 February 2024
09:51	Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)	Zacks Investment Research
Monday, 26 February 2024
11:01	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?	Zacks Investment Research
Sunday, 25 February 2024
13:37	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory	InvestorPlace
Monday, 19 February 2024
14:31	Triple Threat: 3 Stocks to Buy for 3X Upside Potential	InvestorPlace
Thursday, 15 February 2024
10:56	Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?	Zacks Investment Research
08:01	Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?	Zacks Investment Research
Wednesday, 14 February 2024
06:50	New Strong Buy Stocks for February 14th	Zacks Investment Research
Thursday, 4 January 2024
16:30	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Business Wire
Thursday, 14 December 2023
11:16	Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know	Zacks Investment Research
Sunday, 10 September 2023
17:08	Stoke Therapeutics Is Unable To Derisk Its Platform	Seeking Alpha

Ideas & Opinions

Seeking Alpha 16 Jun 2025

Stoke Therapeutics: Impressive Pipeline And Big Backers
Seeking Alpha 10 Jan 2025

NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Seeking Alpha 9 Jul 2024

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Seeking Alpha 14 Jun 2024

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Seeking Alpha 10 Sep 2023

Stoke Therapeutics Is Unable To Derisk Its Platform
Seeking Alpha 12 Feb 2023

Stoke Therapeutics Looks Unfairly Valued
Seeking Alpha 28 Nov 2022

Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome
Seeking Alpha 23 Nov 2022

Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar

Frequently Asked Questions (FAQ)

What's the price of Stoke Therapeutics stock today?

One share of Stoke Therapeutics stock can currently be purchased for approximately $18.3.
When is Stoke Therapeutics's next earnings date?

Unfortunately, Stoke Therapeutics's (STOK) next earnings date is currently unknown.
Does Stoke Therapeutics pay dividends?

No, Stoke Therapeutics does not pay dividends.
How much money does Stoke Therapeutics make?

Stoke Therapeutics has a market capitalization of 609.65M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 29.22% to 8.78M US dollars.
What is Stoke Therapeutics's stock symbol?

Stoke Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "STOK".
What is Stoke Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Stoke Therapeutics?

Shares of Stoke Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Stoke Therapeutics's key executives?
Stoke Therapeutics's management team includes the following people:
- Dr. Edward M. Kaye Chief Executive Officer & Director(age: 76, pay: $958,050)
- Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer(age: 65, pay: $662,500)
- Mr. Stephen J. Tulipano CPA, CPA, MBA Chief Financial Officer(age: 66, pay: $611,450)
- Dr. Adrian R. Krainer Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board(age: 66, pay: $39,000)
Is Stoke Therapeutics founder-led company?

Yes, Stoke Therapeutics is a company led by its founder Dr. Adrian R. Krainer Ph.D..
How many employees does Stoke Therapeutics have?

As Jul 2024, Stoke Therapeutics employs 110 workers.
When Stoke Therapeutics went public?

Stoke Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 19 Jun 2019.
What is Stoke Therapeutics's official website?

The official website for Stoke Therapeutics is stoketherapeutics.com.
Where are Stoke Therapeutics's headquarters?

Stoke Therapeutics is headquartered at 45 Wiggins Avenue, Bedford, MA.
How can i contact Stoke Therapeutics?

Stoke Therapeutics's mailing address is 45 Wiggins Avenue, Bedford, MA and company can be reached via phone at +7 814308200.
What is Stoke Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Stoke Therapeutics in the last 12 months, the avarage price target is $26.5. The average price target represents a 44.80% change from the last price of $18.3.

Stoke Therapeutics, Inc.

stoketherapeutics.com

Exchange:

NASDAQ

Full time employees:

110

Industry:

Biotechnology

Sector:

Healthcare

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

+7 814308200

45 Wiggins Avenue
Bedford, MA 01730

CIK: 0001623526
ISIN: US86150R1077
CUSIP: 86150R107